Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6692MR)

This product GTTS-WQ6692MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6692MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ33MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ1046MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ5756MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ13001MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ2048MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ11003MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ12452MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ7640MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEN1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW